Developing genetically engineered mouse models using engineered nucleases: Current status, challenges, and the way forward

Jaehoon Lee; Jae il Rho; Sushil Devkota; Young Hoon Sung; Han Woong Lee

doi:10.1016/j.ddmod.2017.07.003

Developing genetically engineered mouse models using engineered nucleases: Current status, challenges, and the way forward

Jaehoon Lee, Jae il Rho, Sushil Devkota, Young Hoon Sung, Han Woong Lee

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.

Original language	English
Pages (from-to)	13-20
Number of pages	8
Journal	Drug Discovery Today: Disease Models
Volume	20
DOIs	https://doi.org/10.1016/j.ddmod.2017.07.003
Publication status	Published - 2016 Feb 2

Bibliographical note

Funding Information:
This research was supported by a grant ( 14182MFDS978 ) from Korea Food and Drug Administration in 2015; the National Research Foundation of Korea (NRF) funded by the MEST ( 2015R1A2A1A01003845 ); and a Korean Healthcare Technology R&D Project from the Ministry of Health and Welfare ( A085136 ).

Publisher Copyright:
© 2017 The Author(s)

All Science Journal Classification (ASJC) codes

Molecular Medicine
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ddmod.2017.07.003

Cite this

@article{b25430af6ad34e0f8f4d1d57492321a8,

title = "Developing genetically engineered mouse models using engineered nucleases: Current status, challenges, and the way forward",

abstract = "The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of {\textquoteleft}renaissance in precision genome engineering{\textquoteright} with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these {\textquoteleft}state of the art{\textquoteright} genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.",

author = "Jaehoon Lee and Rho, {Jae il} and Sushil Devkota and Sung, {Young Hoon} and Lee, {Han Woong}",

note = "Funding Information: This research was supported by a grant ( 14182MFDS978 ) from Korea Food and Drug Administration in 2015; the National Research Foundation of Korea (NRF) funded by the MEST ( 2015R1A2A1A01003845 ); and a Korean Healthcare Technology R&D Project from the Ministry of Health and Welfare ( A085136 ). Publisher Copyright: {\textcopyright} 2017 The Author(s)",

year = "2016",

month = feb,

day = "2",

doi = "10.1016/j.ddmod.2017.07.003",

language = "English",

volume = "20",

pages = "13--20",

journal = "Drug Discovery Today: Disease Models",

issn = "1740-6757",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Developing genetically engineered mouse models using engineered nucleases

T2 - Current status, challenges, and the way forward

AU - Lee, Jaehoon

AU - Rho, Jae il

AU - Devkota, Sushil

AU - Sung, Young Hoon

AU - Lee, Han Woong

N1 - Funding Information: This research was supported by a grant ( 14182MFDS978 ) from Korea Food and Drug Administration in 2015; the National Research Foundation of Korea (NRF) funded by the MEST ( 2015R1A2A1A01003845 ); and a Korean Healthcare Technology R&D Project from the Ministry of Health and Welfare ( A085136 ). Publisher Copyright: © 2017 The Author(s)

PY - 2016/2/2

Y1 - 2016/2/2

N2 - The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.

AB - The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.

UR - http://www.scopus.com/inward/record.url?scp=85028568575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028568575&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2017.07.003

DO - 10.1016/j.ddmod.2017.07.003

M3 - Review article

AN - SCOPUS:85028568575

SN - 1740-6757

VL - 20

SP - 13

EP - 20

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

ER -

Developing genetically engineered mouse models using engineered nucleases: Current status, challenges, and the way forward

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this